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ABSTRACT
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients
with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56mg/m2 carfilzomib dose
(KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at
the once-weekly 70mg/m2 carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study
(NCT01998971). We analyzed efficacy data from comparable CANDOR and EQUULEUS patients
using inverse probability of treatment weighting (IPTW)–adjusted models. These weights were
calculated from propensity scores derived to balance prespecified baseline covariates. The side-
by-side and adjusted comparisons showed similar efficacy for overall response rates and pro-
gression-free survival in the two groups, with a series of sensitivity analyses showing consistent
findings. Safety data were generally consistent with the known safety profiles of each individual
drug. Once-weekly KdD70 is comparable to twice-weekly KdD56 in terms of efficacy and safety
while being a more convenient dosing option.
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Regimens containing immunomodulatory imide drugs
(IMiDs) are standard of care for the treatment of newly
diagnosed multiple myeloma [1–5]. With the adoption
of lenalidomide maintenance therapy until disease
progression, there is a further need for effective and
tolerable IMiD-free regimens for patients who progress
on lenalidomide. Worse clinical outcomes are seen in
patients with relapse with IMiD refractoriness when
compared with the overall population [6–9], with
relapse due to various mechanisms of drug resistance
and alterations in the bone marrow microenvironment
[10]. The second-generation proteasome inhibitor (PI)
carfilzomib and the anti-CD38 monoclonal antibody
daratumumab are potent agents in their respective
classes [11–15]. In the phase 3 ENDEAVOR study, carfil-
zomib plus dexamethasone (Kd) showed superiority
over the first-generation PI bortezomib plus dexa-
methasone (Vd) in relapsed and/or refractory multiple
myeloma [11,16]. Likewise, the phase 3 CASTOR study
demonstrated improved clinical outcomes for daratu-
mumab with bortezomib and dexamethasone
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compared with bortezomib and dexamethasone alone
[17]. The regimen including carfilzomib and daratumu-
mab is of high interest to clinicians for relapsed and/
or refractory multiple myeloma.
The randomized phase 3 CANDOR study demon-
strated a statistically significant improvement in progres-
sion-free survival (PFS) for carfilzomib, dexamethasone,
and daratumumab at the twice-weekly 56mg/m2
Figure 1. Overall response rate (ORR) and progression-free survival (PFS) analyses. (A) Unadjusted and adjusted ORR and PFS. The
ORR and PFS and associated 95% confidence intervals (CIs) are shown for twice-weekly (BIW) KdD56 and once-weekly (QW)
KdD70. Also shown are the odds ratios (ORs; for ORR) and hazard ratios (HRs; for PFS) and associated 95% CIs. Sensitivity analyses
for ORR (B) and PFS (C), with corresponding OR for ORR and HR for PFS, and associated 95% CIs are shown for BIW KdD56 and
QW KdD70. Progression-free survival (PFS) for unadjusted primary analysis (D) and IPTW-IRC analysis (E).
BIW: twice-weekly; CI: confidence interval; HR: hazard ratio; IRC: Independent Review Committee; IPTW: inverse probability of treatment weighting; KdD:
carfilzomib, dexamethasone, and daratumumab; NE: not estimable; QW: once weekly.
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carfilzomib dose (KdD56), with a 37% reduction in the
risk of progression or death versus carfilzomib and dexa-
methasone alone (Kd) [18]. Additionally, patients treated
with KdD56 achieved deep responses, with an overall
response rate (ORR) of 84% and a nearly 10 times higher
minimal residual disease (MRD)–negative complete
response (CR) rate compared with Kd-treated patients.
Overall, KdD56 was associated with a favorable benefit-
risk profile. The promising activity of the KdD regimen is
further supported by the non-randomized phase 1b
EQUULEUS study, in which KdD at the once-weekly
70mg/m2 carfilzomib dose (KdD70) showed tolerability
and efficacy, with an ORR of 84% and median PFS of
nearly 26months in patients who were almost all
exposed to lenalidomide and were mostly lenalidomide
refractory [19].
Previously, the phase 3 A.R.R.O.W. study demon-
strated that once-weekly Kd (Kd70) was effective and
safe [20]; this regimen achieved regulatory approval
for the treatment of relapsed and/or refractory mul-
tiple myeloma in the United States and elsewhere.
Patient-reported outcomes from the A.R.R.O.W. study
showed delayed disease symptom worsening as well
as greater convenience and satisfaction with once-
weekly Kd70 as compared with twice-weekly Kd27.
Improved clinical outcomes for the once-weekly Kd
regimen translated into prolonged health-related qual-
ity of life in a cost-effective manner [21,22]. Thus, as
observed with the Kd regimen, once-weekly carfilzo-
mib dosing with KdD is expected to improve patients’
quality of life by allowing patients to maintain a social
role and other meaningful activities, which is key from
a patient’s perspective [23].
While we expect that the once-weekly KdD70 regi-
men would provide patients a more convenient treat-
ment option and thus better adherence, the two
regimens of twice-weekly KdD56 and once-weekly
KdD70 have not been directly compared in a random-
ized trial. Therefore, we performed a robust cross-
study comparison that demonstrated similar efficacy
and safety, which was confirmed with sensitiv-
ity analyses.
Table 1. Unadjusted baseline demographics and disease characteristics.
CANDOR Subset






Sex, male, n (%) 105 (57%) 46 (54%)
Age group, n (%)
<65 years 100 (54%) 36 (42%)
65–74 years 73 (40%) 41 (48%)
75 years 12 (7%) 8 (9%)
Race, n (%)
Asian 33 (18%) 3 (4%)
Black or African American 6 (3%) 3 (4%)
White 132 (71%) 68 (80%)
Other 14 (8%) 0 (0%)
Missing 0 (0%) 11 (13%)
ECOG performance status, 0 / 1–2, % 48% / 52% 38% / 62%
Creatinine clearance, n (%)
<50mL/min 19 (10%) 15 (18%)
50–79mL/min 57 (31%) 28 (33%)
80mL/min 108 (58%) 42 (49%)
Risk group by FISH, %
High risk 16% 15%
t(4;14) / t(14;16) / del(17p) 6.5% / 0.5% / 9.7% 7.1% / 2.4% / 8.2%
Standard risk 31% 64%
Unknown 53% 21%
Time from diagnosis, months, mean (SD) 46 (30) 57 (30)
Time from diagnosis, months, median (range) 37 (0.3–157) 49 (8.7–145)
Prior regimens, 1 / 2, n (%) 62 (34%) / 123 (66%) 20 (24%) / 65 (76%)
Prior transplant, n (%) 129 (70%) 62 (73%)
Refractory to last prior treatment, n (%) 124 (67%) 53 (62%)
Time from last relapse, months, mean (SD) 3.2 (6.3) 2.7 (5.9)
Received prior IMiD, n (%) 185 (100%) 85 (100%)
Received thalidomide 102 (55%) 21 (25%)
Received lenalidomide 115 (62%) 81 (95%)
Refractory to prior lenalidomide 94 (51%) 50 (59%)
Received prior PI, n (%) 185 (100%) 85 (100%)
Refractory to prior bortezomib, n (%) 57 (31%) 27 (32%)
BIW: twice weekly; ECOG: Eastern Cooperative Oncology Group; FISH: fluorescence in situ hybridization; IMiD: immunomodulatory imide drug; KdD: carfil-
zomib, dexamethasone, and daratumumab; PI: proteasome inhibitor; QW: once weekly; SD: standard deviation.
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Methods
Study design
CANDOR is a phase 3, open-label, multicenter,
randomized study in patients with relapsed and/or
refractory multiple myeloma who received 1–3 prior
lines of therapy (NCT03158688). Patients were random-
ized 2:1 to receive KdD or Kd in 28-day cycles until
disease progression (Figure S1A, Table S1). Treatment
continued until confirmed disease progression,
unacceptable toxicity, consent withdrawal, or death
(whichever occurred first), and lasted up to 48months.
The primary endpoint was PFS; secondary endpoints
were ORR, MRD-negative CR rate at 12months, overall
survival (OS), time to response, and safety. Data are
through July 14, 2019 (primary analysis date).
EQUULEUS is a phase 1 b, multicenter, open-label,
multiarm, non-randomized study of daratumumab in
combination with other agents in patients with
relapsed and/or refractory multiple myeloma
(NCT01998971) (Figure S1B, Table S1). One cohort
combined daratumumab with carfilzomib and dexa-
methasone (i.e. KdD), which is the dataset described
here and elsewhere [19]. Patients received 1–3 prior
lines of therapy, including bortezomib and an IMiD.
Treatment continued until confirmed disease progres-
sion, unacceptable toxicity, withdrawal of consent,
death, or end of study, which was approximately
25months after the last patient received the first dose
of daratumumab or when 38 PFS events were
reached. The primary endpoints were safety and toler-
ability. Secondary endpoints included ORR and OS;
PFS was an exploratory endpoint. Data are through
January 31, 2019 (final analysis date for this cohort). In
the original report, the number of patients evaluable
for response per study criteria was 82 of 85; all 85
patients are included in our analyses.
Statistical analysis
This cross-study comparison was a prespecified meta-
analysis exploring the similarity between the efficacy
and safety outcomes for patients treated with the trip-
let combination KdD in two different studies. The effi-
cacy data were analyzed both unadjusted and with
propensity score adjustment, while safety data were
summarized in side-by-side tables.
In order to evaluate efficacy in comparable popula-
tions, as all patients from the EQUULEUS KdD cohort
were required to have prior therapy with bortezomib
and an IMiD, similar patients (i.e. those with prior bor-
tezomib and IMiD exposure) were selected from the
CANDOR KdD arm; 185 of the 312 patients in the
CANDOR study receiving KdD met this requirement.
All these patients had at least one study treatment
dose and were included in the safety summaries. The
efficacy endpoints were derived based on the
response and disease progression from both studies
assessed post hoc by the same blinded Independent
Review Committee (IRC). The PFS endpoint was ana-
lyzed using Cox models, while the Kaplan-Meier meth-
odology was used to summarize its distribution,
including the point estimates and 95% confidence
intervals (CIs) for medians [24]. ORRs were calculated
as the rate of responders who achieved a partial
response (PR) or better and associated 95% CIs were
estimated with the Clopper-Pearson method. Odds
ratios (ORs) were evaluated with logistic models, while
95% CIs were constructed with robust vari-
ance estimates.
For efficacy comparisons, results were adjusted with
inverse probability of treatment weighting (IPTW). The
weights were calculated using the propensity score
that a patient received once-weekly KdD70 by balanc-
ing the baseline covariates that had been preselected
as prognostic for multiple myeloma. Selection of these
covariates was independent of prior knowledge of effi-
cacy outcomes and was based on subject matter
expert guidance and literature review. The covariates
included baseline demographics (age), disease charac-
teristics (prior treatment exposure/refractoriness and
time from initial diagnosis to relapse), and other char-
acteristics (creatinine clearance, Eastern Cooperative
Oncology Group [ECOG] performance status), many of
which have been evaluated in previous carfilzomib
analyses [25]. We did not include all components of
the revised International Staging System (R-ISS) as
data were not available for all patients for fluores-
cence in situ hybridization (FISH) and as b2 microglo-
bulin data were not collected in the EQUULEUS study.
The appropriateness of the model was assessed by
boxplots and absolute standardized difference, evalu-
ating the balance reached between the two groups
after weighting adjustment. Propensity score matching
was also used as a sensitivity analysis by sequentially
matching patients based on greedy nearest neighbor
matching of the propensity scores derived for the
IPTW method. Propensity score matching creates
mutually exclusive sets of observations that have simi-
lar propensity scores. Greedy nearest neighbor match-
ing was used to sequentially match each patient in
the KdD70 cohort with one patient in the KdD56
external control group if the difference in the logits of
the propensity score for pairs of patients from the two
QW KdD70 COMPARABLE TO BIW KdD56 361
groups was less than or equal to 0.1 times the pooled
estimate of the standard deviation [26,27]. Efficacy
endpoints derived based on unblinded evaluations by
the investigators were included as a sensitivity ana-
lysis. In addition, PFS and ORR were analyzed within
prespecified subgroups, including by the number of
prior regimens, prior transplant, refractoriness to PIs or
IMiDs, age, ECOG performance status, and baseline
creatinine clearance. The hazard ratios (HRs; with 95%
CIs) for PFS and ORs (with 95% CIs) for ORR between
treatment groups within each subgroup were esti-
mated using the same methodology as for the over-
all analysis.
Results
Demographic and baseline characteristics
Baseline demographic and disease characteristics were
generally comparable between the two groups in this
analysis: twice-weekly KdD56 CANDOR arm (i.e.
CANDOR subset with prior bortezomib and IMiD
exposure) and once-weekly KdD70 EQUULEUS cohort.
However, some baseline characteristics were imbal-
anced across the studies (Table 1). Specifically, in the
KdD70 cohort, more patients had a higher ECOG per-
formance status, at least two prior treatments, and
prior exposure to lenalidomide, and disease duration
was longer than in the KdD56 arm. Following IPTW
adjustment, baseline and disease characteristics
considered prognostic were balanced for the two
groups (Table 2).
At the time of this analysis, 48% of CANDOR
patients and 41% of EQUULEUS patients were continu-
ing treatment. Of patients who discontinued treat-
ment, the most common reasons for discontinuation
were disease progression (CANDOR: 27%, EQUULEUS:
42%), adverse events (AEs, 10%, 6%), and per patient
request (7%, 7%) (Table S2).
Efficacy
In a side-by-side comparison, after a median follow-up
of 16.8months, median PFS for the KdD56 group was
not reached (not estimable [NE]; 95% CI, 18.4–NE),
whereas for the KdD70 cohort, median PFS was
25.8months (95% CI, 19.4–NE, median follow-up of
23.5months) (Table 3, Figure 1(A)). PFS event-free
rates at 12months were 64.9% (95% CI: 57.3%–71.4%)
for KdD56 and 75.2% (95% CI: 64.2%–83.2%) for
KdD70 (graph in Figure 1(D,E)). ORR was 83.2% (95%
CI, 77.1%–88.3%) for KdD56 and 81.2% (95% CI,
71.2%–88.8%) for KdD70. After IPTW adjustment, the
95% CI for the HR for PFS and the OR for ORR
included 1, showing similar efficacy for the KdD56 and
KdD70 groups (median PFS, NE and 25.8months,
respectively [HR, 0.80; 95% CI, 0.49–1.32]; ORR, 79.6%
and 81.2%, respectively [OR, 1.11; 95% CI, 0.50–2.45]).












Age group, n (%)
<65 years 34.2 (38.3%) 36.0 (42.4%)
65–74 years 45.8 (51.3%) 41.0 (48.2%) 0.06
75 years 9.3 (10.4%) 8.0 (9.4%) 0.03
ECOG performance status, %, 0 / 1–2 34.6% / 65.4% 37.6% / 62.4% 0.06
Time from initial diagnosis, months, mean (SD) 57.2 (21.8) 57.3 (29.8) <0.01
Creatinine clearance, n (%)
<50mL/min 16.0 (17.9%) 15.0 (17.6%)
50–79mL/min 34.2 (38.3%) 28.0 (32.9%) 0.11
80mL/min 39.1 (43.8%) 42.0 (49.4%) 0.11
Prior regimens, 1 / 2, % 28.0% / 72.0% 23.5% / 76.5% 0.10
Prior transplant, % 73.6% 72.9% 0.01
Refractory to last prior treatment, % 60.0% 62.4% 0.05
Time from last relapse, months, mean (SD) 2.81 (2.44) 2.72 (5.94) 0.02
Received lenalidomide, n (%) 85.3 (95.6%) 81.0 (95.3%) 0.01
Refractory to prior lenalidomide, n (%) 47.9 (53.6%) 50.0 (58.8%) 0.10
Refractory to prior bortezomib, n (%) 26.7 (29.9%) 27.0 (31.8%) 0.04
BIW: twice weekly; ECOG: Eastern Cooperative Oncology Group; IMiD: immunomodulatory imide drug; KdD: carfilzomib, dexamethasone, and daratumu-
mab; QW: once weekly; SD: standard deviation. Absolute standard difference was a prespecified method used to quantify the balance for each covariate;
an absolute standard difference of 0.1 signifies little or no imbalance between KdD BIW and KdD QW for that variable.
aThe N¼ 89.3 is not a whole number as it represents a weighted sum of the 185 KdD56 CANDOR patients included in the analysis. Specifically, each
patient of the KdD56 arm was weighted according to the inverse probability of treatment weighting (IPTW) based on the propensity score to have
received KdD70, balancing for the baseline covariates included in this table. As these weights were not whole numbers, the sum of these weights was
also not necessarily a whole number (in this case, the sum was 89.3).
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Additional sensitivity analyses were performed to
support the robustness of the main comparison
results. One sensitivity analysis for efficacy results
adjusted for IPTW using an extended list of covariates,
specifically laboratory values for albumin, hemoglobin,
lactate dehydrogenase (LDH), and platelet count, and
the presence of plasmacytoma, in addition to the
covariates included in the main analysis, yielded con-
sistent results. Efficacy results adjusted by propensity
score matching showed similar results as well. In
another sensitivity analysis, the adjusted and
unadjusted comparisons performed on investigator-
assessed ORR and PFS yielded similar findings to those
performed on IRC-assessed ORR and PFS (Figure
1(B,C), Tables SIII, SIV). Prespecified subgroup analyses
(e.g. number of prior regimens, prior transplant, refrac-
toriness to PIs or IMiDs, age, ECOG performance status,
baseline creatinine levels) were consistent with the
results from the main analysis for PFS and ORR out-
comes, including in the lenalidomide-refractory sub-
group and by prior transplant status (Table 4).
Exposure and safety
The median duration of carfilzomib treatment was
shorter for the twice-weekly KdD56 group (54.3weeks)
than for the once-weekly KdD70 cohort (66.0weeks)
and the median relative dose intensity was similar for
both groups at approximately 90%. Safety analyses
were performed side-by-side for all patients with no
adjustment. All-grade treatment-emergent adverse
events (TEAEs) occurred in 100% of patients in both
groups (Table 5). Over the course of the studies (i.e.
not duration-adjusted), the unadjusted frequency of
grade 3 TEAEs was similar in the KdD56 and KdD70
groups (84.3% and 82.4%, respectively), while the inci-
dence of serious (58.9% and 48.2%) and fatal (10.8%
and 3.5%) TEAEs was higher in the KdD56 group. For
fatal AEs, of the 20 in the KdD56 group, 10 were due
to infections (five septic shock, four pneumonia, one
respiratory tract infection), whereas for the three fatal
AEs in the KdD70 cohort, two were due to general
physical health and one due to multiple organ dys-
function. The proportions of patients with AEs leading
to carfilzomib discontinuation (21.1% for KdD56 and
18.8% for KdD70) and daratumumab discontinuation
(8.1% and 8.2%) were comparable between the two
treatment groups. For AEs of interest, the rates of
grade 3 AEs in the KdD56 and KdD70 groups,
respectively, were 1.1% and 2.4% for cardiac failure,
0.5% and 3.5% for acute renal failure, 18.4% and
20.0% for hypertension, and 2.7% and 0.0% for
respiratory tract infections. For the category of grade
3 infections/infestations, the rate was higher with
KdD56 than with KdD70 (36.8% and 21.2%, respect-
ively). These same general trends were seen in expos-
ure-adjusted rates of AEs; however, conclusions are
limited as there were relatively few events for several
AEs of interest in both studies.
Discussion
The KdD regimen is recommended by the National
Comprehensive Cancer Network (NCCN 2020, version
3) guidelines for patients with previously treated mul-
tiple myeloma [4]. As weekly carfilzomib dosing can
be more convenient and improve the quality of life
[21,22], we undertook rigorous efficacy analyses in this
cross-study comparison to support the comparability
of twice-weekly KdD56 to once-weekly KdD70. We
found that the corresponding groups of the CANDOR
and EQUULEUS studies showed similar efficacy in
terms of ORR and PFS, both before and after IPTW
adjustment, including in patients who were refractory
to lenalidomide and independent of past stem cell
transplant status. We also examined safety in side-by-
side unadjusted analyses and found that the safety
profiles of KdD56 and KdD70 were generally consist-
ent with the known safety profiles of the individual
agents. The proportions of patients with grade 3 AEs
were similar in the KdD56 and KdD70 groups and the
incidences of grade 3 cardiac AEs, renal failure,
hypertension, and respiratory tract infections did not
differ appreciably. However, there were more grade
3 infectious AEs and fatal infections with KdD56
Table 3. Unadjusted and adjusted ORR and PFS.









































BIW: twice weekly; CI: confidence interval; HR: hazard ratio; KdD: carfilzo-
mib, dexamethasone, and daratumumab; NE: not estimable; OR: odds
ratio; ORR: overall response rate; PFS: progression-free survival; QW:
once weekly.
aThe N¼ 89.3 is not a whole number as it represents a weighted sum of
the 185 KdD56 CANDOR patients included in the analysis. Specifically,
each patient of the KdD56 arm was weighted according to the inverse
probability of treatment weighting (IPTW) based on the propensity score
to have received KdD70, balancing for the baseline covariates included
in this table. As these weights were not whole numbers, the sum of
these weights was also not necessarily a whole number (in this case, the
sum was 89.3).
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than with KdD70. Although the benefit-risk profile was
similar for both regimens, the once-weekly carfilzomib
regimen may be more convenient for patients and
healthcare providers. The more convenient regimen
may improve adherence to the on-label carfilzomib
dosing and frequency, and thus optimize carfilzomib
dose intensity and outcomes in the real-world setting,
as suboptimal carfilzomib dose intensity has been
shown to be associated with poorer outcomes [28].
Direct comparisons across studies can be con-
founded by differences in study design, including eli-
gibility criteria that result in patient populations with
different characteristics, such as prior treatment his-
tory, leading to biased estimates of treatment effects
[29–33]. To account for this, the propensity score
method was used to balance prespecified baseline
covariates selected to be prognostic for multiple mye-
loma, with the goals of controlling for potential con-
founding factors of cross-trial comparison and
minimizing selection bias. The IPTW/propensity score
approach is a well-established method intended to
mirror the effects of randomization [34,35]. Specifically,
adjustment for selection bias was done by weighting
the data based on the propensity score that a patient
received once-weekly KdD70. As IPTW is based on
covariates selected as prognostic for multiple mye-
loma outcomes, the methodology was applied to effi-
cacy data, but not to safety events. Other studies
evaluating treatment outcomes among patients with
hematologic malignancies have also used propensity





Overall response rate odds ratio (95% CI)
All patients in analysis 0.87 (0.45–1.69) 1.11 (0.50–2.45)
Refractory to lenalidomide
Yes 0.72 (0.32–1.62) 0.64 (0.28–1.46)
No 1.62 (0.43–6.13) 3.18 (0.67–15.11)
Prior stem cell transplanta
Yes 0.77 (0.35–1.69) 1.17 (0.45–3.02)
No 1.16 (0.33–4.11) 0.93 (0.24–3.53)
Progression-free survival hazard ratio (95% CI)
All patients in analysis 0.87 (0.57–1.32) 0.80 (0.49–1.32)
Refractory to lenalidomide
Yes 1.22 (0.70–2.10) 1.25 (0.71–2.20)
No 0.54 (0.27–1.05) 0.43 (0.19–1.00)
Prior stem cell transplant
Yes 0.82 (0.51–1.34) 0.77 (0.42–1.40)
No 0.94 (0.42–2.14) 0.87 (0.36–2.11)
BIW: twice weekly; CI: confidence interval; IPTW: inverse probability of treatment weighting; IRC: Independent Review
Committee; KdD: carfilzomib, dexamethasone, and daratumumab; QW: once weekly.
aFor CANDOR patients, prior transplant includes autologous and allogeneic transplant; for EQUULEUS patients, prior transplant
includes autologous transplant only.
Table 5. Safety.
CANDOR Subset







# per 100 patient-years




All treatment-emergent adverse events 185 (100.0) NC 85 (100.0) NC
Grade 3 156 (84.3) 229 (196–268) 70 (82.4) 173 (137–219)
Serious adverse events 109 (58.9) 85 (70–102) 41 (48.2) 46 (34–62)
Leading to D/C carfilzomib 39 (21.1) 22 (16–30) 16 (18.8) 15.1 (9.3–24.6)
Leading to D/C daratumumab 15 (8.1) 8.2 (4.9–13.5) 7 (8.2) 6.1 (2.9–12.8)
Fatal adverse events 20 (10.8) 10.6 (6.8–16.4) 3 (3.5) 2.6 (0.8–7.9)
Adverse events of interest, grade 3
Cardiac failure 2 (1.1) 1.1 (0.3, 4.3) 2 (2.4) 1.8 (0.4, 7.0)
Acute renal failure 1 (0.5) 0.5 (0.1, 3.8) 3 (3.5) 2.6 (0.8, 8.0)
Hypertension 34 (18.4) 20.8 (14.8, 29.1) 17 (20.0) 17.6 (11.0, 28.3)
Respiratory tract infections 5 (2.7) 2.7 (1.1, 6.5) 0 (0.0) 0.00 (NA, NA)
Infections / infestationsa 68 (36.8) 44.5 (35.1, 56.4) 18 (21.2) 18.3 (11.5, 29.0)
BIW: twice weekly; CI: confidence interval; D/C: discontinuation of; KdD: carfilzomib, dexamethasone, and daratumumab; NA: not applicable; QW: once
weekly. NC indicates that exposure-adjusted adverse event rates were not calculated as collection of adverse events can vary across studies, making
interpretation of rates of all adverse events across studies infeasible. Safety data were compared side-by-side without any propensity score adjustment.
aBy system organ class category; other adverse events are preferred terms.
364 X. LELEU ET AL.
score analysis to compare two distinct study popula-
tions and achieve balance in baseline factors [36,37].
Besides possible confounding due to the nature of
cross-study comparisons, another limitation of this
analysis was that baseline covariates in this analysis
did not include R-ISS as b2 microglobulin data were
not collected in the EQUULEUS study and as FISH data
were not available for many patients in both studies.
However, LDH and albumin levels, two components of
R-ISS, were used as additional variables, along with
platelet count, hemoglobin, and plasmacytoma pres-
ence, in a sensitivity analysis. In this sensitivity ana-
lysis, there appears to be a larger effect size
associated with KdD70 versus KdD56 for both ORR
and PFS. This sensitivity analysis may have reduced
residual confounding; however, the 95% CIs still
included 1.
Previously, once-weekly carfilzomib dosing with
Kd70 was shown to have improved patients’ quality of
life with improved clinical outcomes relative to twice-
weekly carfilzomib dosing [21–23]. In line with these
results for the once-weekly Kd70 doublet regimen, we
expect that the once-weekly KdD70 triplet regimen
will provide patients a more convenient lenalidomide-
free treatment option, thus fostering adherence to the
treatment schedule, dose, and treatment duration.
Future analyses could confirm whether a weekly regi-
men is associated with better adherence and
improved responses and survival. In addition, in the
era of COVID-19, guidelines have recommended
switching patients from twice-weekly to weekly carfil-
zomib at an appropriate dose [38,39], thus decreasing
patients’ potential exposure to coronavirus as well as
enabling adherence and reducing strain on the health-
care system during a time when non-emergent visits
to healthcare facilities should be limited. As the
recently approved subcutaneous daratumumab [40]
becomes more widely available, the treatment option
of weekly KdD may result in further improvements in
patient satisfaction, since use of subcutaneous daratu-
mumab has been associated with higher patient satis-
faction versus intravenous daratumumab [41], as
would be expected with reduced infusion chair time
and decreased infusion-related reactions.
In conclusion, this cross-study analysis showed that
once-weekly KdD70 in the EQUULEUS study is compar-
able to the twice-weekly KdD56 regimen used in the
pivotal phase 3 CANDOR trial in terms of efficacy and
safety. The weekly KdD70 dosing option addresses an
important need for patients by providing a more con-
venient lenalidomide-free regimen that may
encourage adherence and potentially lead to
improved outcomes for patients.
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